PROCHLORPERAZINE MALEATE MARKET ANALYSIS

Prochlorperazine Maleate Market, By Indication (Nausea and Vomiting Management, Vertigo, Motion Sickness), By Dosage Form (Oral Tablets, Rectal Suppositories, Injectable Formulations), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End User (Hospitals, Clinics, Ambulatory Surgical Centers, Homecare Settings), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Recent Developments

New product launches

On August 11, 2022, Zydus Lifesciences, a pharmaceutical company based in India received final approval from the U.S. FDA to market market Prochlorperazine Maleate tablets, USP 5 mg, and 10 mg.

Acquisition and partnerships

On August 29, 2022, ANI Pharmaceuticals, Inc. announced the launch of Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg., ANI's Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg are the generic version of the Reference Listed Drug (RLD) Compazine and were developed in technical collaboration with Biophore India Pharmaceuticals Pvt. Ltd., a pharmaceutical company based in India.